Novartis Pharma AG reported final Phase III results from the ALIGN study showing that Vanrafia (atrasentan) slowed kidney function decline in adults with IgA nephropathy compared with placebo through Week 136. The data are intended to support conversion from accelerated approval, granted in 2025 in the United States and China for reduction of proteinuria, to traditional approval in 2026. The readout moves the conversation from surrogate biomarker reduction to durability of renal protection in a chronic, progressive disease.

The strategic shift is substantial. Accelerated approval for IgA nephropathy therapies has largely depended on proteinuria reduction as a reasonably likely surrogate endpoint. However, regulators expect confirmatory trials to demonstrate that biomarker improvement translates into sustained preservation of kidney function. ALIGN was structured to test that premise.

How the ALIGN eGFR slope data reshape the evidentiary threshold beyond proteinuria

The headline outcome was a 2.39 ml/min/1.73 m² difference in estimated glomerular filtration rate change from baseline versus placebo at Week 136, measured four weeks after treatment cessation. The two-sided p-value of 0.057 narrowly exceeded the conventional 0.05 benchmark. At Week 132, the end-of-treatment timepoint, the difference reached 2.59 ml/min/1.73 m² with a nominal p-value of 0.039.

Regulatory evaluation will not hinge on a single statistical boundary. Instead, reviewers will assess consistency across timepoints, slope robustness, and biological plausibility. In IgA nephropathy, long-term eGFR trajectory often carries more clinical weight than isolated cross-sectional differences. Sustained separation over nearly three years strengthens the argument that atrasentan’s impact extends beyond transient hemodynamic effects.

Duration itself is part of the evidence. ALIGN represents one of the longest follow-up periods among pivotal IgA nephropathy trials. Chronic kidney disease progresses slowly, and extended observation enhances confidence that slope modification reflects disease alteration rather than short-term fluctuation.

The key regulatory question is whether earlier proteinuria reductions, which underpinned accelerated approval, are now supported by durable kidney function preservation. If the evidentiary chain holds, the pathway to traditional approval becomes more coherent.

What this changes in a treatment landscape defined by SGLT2 inhibitors and targeted competition

The IgA nephropathy landscape has evolved rapidly. Sodium-glucose co-transporter-2 inhibitors are now widely embedded in standard care for chronic kidney disease. Any new therapy must demonstrate incremental benefit on top of optimized background regimens.

ALIGN reported favorable findings in the prespecified exploratory subgroup of patients receiving sodium-glucose co-transporter-2 inhibitors. This detail is strategically important. Demonstrating additive benefit in the context of modern therapy positions Vanrafia as complementary rather than disruptive.

Mechanistically, atrasentan targets the endothelin pathway, distinct from complement inhibition and other immunologic approaches advancing in IgA nephropathy. This differentiation may support rational combination strategies for patients with persistent proteinuria or progressive decline despite optimized care.

Within Novartis Pharma AG’s renal portfolio, Fabhalta, known as iptacopan, and the investigational compound zigakibart broaden mechanistic coverage. Whether Vanrafia ultimately serves as foundational therapy or competes for sequencing priority will depend on comparative durability, safety, and payer positioning.

Reimbursement dynamics will influence uptake. As targeted renal therapies multiply, payers may demand clearer patient stratification and real-world outcome validation before endorsing combination use.

Where the data may face pressure points during regulatory and clinical review

Despite positive topline framing, ALIGN will undergo rigorous interpretation.

The Week 136 p-value of 0.057 sits close to conventional significance thresholds. Regulatory agencies typically evaluate totality of evidence rather than applying rigid cutoffs, yet the near-boundary result will prompt detailed examination of multiplicity control, hierarchical testing, and sensitivity analyses. The Week 132 nominally significant finding strengthens the case but does not eliminate statistical nuance.

Clinical magnitude will also be contextualized. A 2 to 3 ml/min/1.73 m² difference over roughly three years may appear modest numerically. However, chronic kidney disease progression is measured in slope. Even incremental annual preservation can translate into delayed dialysis initiation over longer horizons. Interpretation will depend on comparison with historical progression rates and competing late-stage datasets.

Safety remains central. Endothelin receptor antagonists have historically raised concerns related to fluid retention and cardiovascular effects. ALIGN reportedly showed a safety profile consistent with prior findings and no emergent long-term signals. Nonetheless, broader real-world use often reveals nuances not fully captured in controlled trials.

Generalizability will also influence adoption. Trial populations may not reflect the full heterogeneity of routine nephrology practice. Clarity around which patient subsets derive the greatest benefit will guide clinician confidence and payer acceptance.

What ALIGN signals about evolving evidentiary standards in IgA nephropathy development

The trajectory of IgA nephropathy drug development is shifting from short-term biomarker reduction toward validated slope preservation. Early programs focused heavily on proteinuria as a surrogate endpoint. While still relevant, durable eGFR benefit is increasingly viewed as the defining marker of disease modification, particularly in a condition where progression unfolds over years rather than months.

ALIGN reflects that evolution. By extending follow-up to 136 weeks and focusing on longitudinal kidney function trends rather than isolated timepoint comparisons, Novartis Pharma AG aligns its development strategy with tightening regulatory expectations. The design implicitly acknowledges that conversion from accelerated approval requires a persuasive bridge from biomarker change to structural renal preservation.

Clinicians following the field emphasize durability, reproducibility, and compatibility with contemporary standards of care. Therapies that demonstrate consistent benefit alongside sodium-glucose co-transporter-2 inhibitors are more likely to secure stable algorithmic positioning. Equally important is the magnitude and consistency of slope separation across subgroups, which informs confidence in long-term disease modification rather than transient hemodynamic adjustment.

The 2026 regulatory submission will therefore test not only Vanrafia’s dataset but the broader maturation of accelerated approval pathways in nephrology. Regulators may weigh the totality of evidence, including mechanistic plausibility, consistency of proteinuria reduction, durability of eGFR preservation, and safety stability over extended exposure. Industry observers suggest that confirmatory trials in kidney disease are increasingly judged on narrative coherence across endpoints rather than statistical thresholds alone.

If regulators accept ALIGN as confirmatory, the decision could reinforce a development model in which early surrogate-based approvals transition to validated clinical benefit through extended slope analysis. If further clarification is requested, it may signal that evidentiary standards in chronic kidney disease are continuing to rise as the therapeutic field becomes more competitive and data-rich.

At present, the results strengthen the argument that atrasentan may extend beyond proteinuria control toward measurable preservation of renal function within a modern treatment framework. Whether that argument is considered sufficiently robust for traditional approval will become clear during regulatory review, but ALIGN undeniably raises the bar for how IgA nephropathy therapies are evaluated in late-stage development.

  ALIGN study, atrasentan, chronic kidney disease, eGFR slope, endothelin receptor antagonist, Fabhalta, IgA nephropathy, iptacopan, Novartis Pharma AG, Vanrafia